Weight-Loss drugs may have secret heart benefits – new study investigates

NCT ID NCT07483801

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study looks at how the diabetes and weight-loss drugs semaglutide and tirzepatide directly affect blood vessels and heart function, beyond their known effects on weight. Researchers will infuse the drugs into the arm or bloodstream of 112 volunteers with different body weights and blood pressures. The goal is to understand why these drugs lower blood pressure, which could lead to better treatments for heart disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide and tirzepatide
What this could lead to
If it works, this could help explain how these drugs lower blood pressure beyond just weight loss, potentially leading to better heart treatments.
What could go wrong
This is a small, early pilot study (Phase 4) with only 112 participants, so results may not apply to everyone. It is designed to gather information, not to prove a treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Addenbrooke's Hospital

    Cambridge, Cambridgeshire, CB20QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.